(Q37109643)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

8 March 2020

main subject

0 references

author

Patrizia Vici

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Isabella Sperduti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Antonio Frassoldati

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Clara Natoli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Luca Moscetti

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Stefania Gori

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Diana Giannarelli

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Paolo Marchetti

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Domenico Sergi

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Maddalena Barba

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Marcello Maugeri

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Laura Iezzi

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Filippo Montemurro

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

32

Ruggero De Maria

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

6

Teresa Gamucci

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

2

Laura Pizzuti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

24

Lucia Mentuccia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

8

Andrea Michelotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

13

Alessandra Cassano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

7

Silverio Tomao

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

19

Valentina Sini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

29

Ilaria Bertolini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

11

Editta Baldini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

12

Francesco Giotta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

25

Loretta D'Onofrio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

27

Angelo Fedele Scinto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

14

Daniele Santini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Luigi Di Lauro

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Domenico Cristiano Corsi

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Michelangelo Russillo

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Lucia Da Ros

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Maria Luisa Basile

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Valentina Rossi

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

1 April 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

17932-17944

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

8 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Triple positive breast cancer: a distinct subtype?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Effect of HER2 status on distant recurrence in early stage breast cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Comprehensive molecular portraits of human breast tumours

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Trastuzumab containing regimens for early breast cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Metastatic behavior of breast cancer subtypes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Annual hazard rates of recurrence for breast cancer after primary therapy.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

HER2 and hormone receptor-positive breast cancer--blocking the right target

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

20 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4951261

A note on quantifying follow-up in studies of failure time

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26910921

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Time-dependence of hazard ratios for prognostic factors in primary breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26910921

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26910921

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.7480

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910921%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference